Non-Hodgkinęs lymphomas in childhood in Slovak republic – the incidence and treatment results
Authors:
E. Bubanská 1; E. Kaiserová 2; I. Oravkinová 3; J. Horáková 4; D. Petržalková 2
Authors‘ workplace:
Klinika pediatrickej onkológie a hematológie SZU v DFNsP, Banská Bystrica
1; Detská onkologická klinika LF UK a DFNsP, Bratislava
2; Oddelenie detskej hematológie a onkológie DFN, Košice
3; Transplantačná jednotka kostnej drene II. Detskej kliniky LF UK a DFNsP, Bratislava
4
Published in:
Transfuze Hematol. dnes,16, 2010, No. 1, p. 6-16.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Background:
The aim of the study is to evaluate the incidence and treatment results in children and adolescent with non-Hodgkin’s lymphomas in Slovak republic since the treatment was unificated in three centers of pediatric oncology and to compare these results with those in previous period and with results in progressive international groups. Patients and methods: In a retrospective study the incidence, subgroups of lymphomas in individual centers, treatment results, relapses, cause of death, transplantation activity in patients treated according to protocols NHL BFM 95, EURO-LB 02, B-NHL BFM 04 a ALCL 99 is analyzed during the period between November 1996 to December 2008. Results: Incidence of lymphomas is analysed in 102 patients and treatment results in 99 eligible patients. There are 26 patients (25.5%) with lymphoblastic lymphoma, 55 (53.9%) with mature B-cell lymphomas, 18 (17.7%) with anaplastic large cell lymphoma and 3 (2.9%) with another lymhomas. Complete remission was achieved in 83 children (83.8%) of the whole group of patients and in 25 (96 %) of lymphoblastic lymhoma, 42 (76.3%) of mature B-cell lymphomas and 16 (88.9%) of anaplastic large cell lymphoma subgroups. Relapse occurred in 5 patients (5.1%), 18 patients died (18.2%) and 81 patients (81.2%) are alive in period of 2–144 months (median 50 months). 5 patient were transplanted. 5-year event free survival is 0.75 in the whole group, in lymphoblastic lymphoma, mature B-cell lymphomas and anaplastic large cell lymphoma 0.78; 0.72; 0.77. 5-year overall survival is 0.81 in the whole group, in lymphoblastic lymphoma, mature B-cell lymphomas and anaplastic large cell lymphoma 0.92; 0.75; 0.81. Conclusions: The results in the study group has improved in comparison to the previous period, but they still have not reached the results of other multicenter international groups. In order to improve the results an effort to decrease the number of toxic deaths should be pursued as the first option.
Key words:
non-Hodgkin’s lymphomas, childhood, treatment results
Sources
1. Lymfómová skupina Slovenskej republiky: Stratégia liečby malígnych lymfómov. Princípy klasifikácie, diagnostiky a liečby malígnych lymfómov.1. vydanie-január 2007, 7-79.
2. Jaffe ES, Harris NL, Stein H et al. Pathology and genetics of tumours of haematopoietic and lymphoid tisssues: World Health Organization classification of tumours. Lyon, France, IARC Press, 2001.
3. Kaatsch P, Spix C. German Childhood Cancer Registry, annual report 2003. German Childhood Cancer Registry, Mainz, Germany, 2004.
4. Kaiserová E, Bubanská E, Oravkinová I, Stančoková T, Šubová Z, Plank L. Incidencia a kurabilita nádorov v detskom veku v Slovenskej republike. Onkológia 2006; 3: 180-186.
5. Cairo MS, Raetz E, Lim MS, et al. Childhood and adolescent Non-Hodgkin lymphoma: new insights in biology and critical challenges for the future. Pediatr Blood Cancer 2005; 45: 753-769.
6. Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haemat 2005; 131: 39-49.
7. Pinkerton CR. The continuing challenge of treatment for non-Hodgkin’s lymphoma in children. Br J Haemat 1999; 107: 220-234.
8. Grenzebach J, Schrappe M, Ludwig WD, et al. Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy. Ann Hematol 2001; 80(Suppl. 3): B73-B76.
9. Oillon M, Di Tullio MT, Garaventa A, et al. Long-term results of the first Italian association of pediatric hematology and oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92). Cancer 2004; 101: 385-394.
10. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification od therapy: A report of the Berlin-Frankfurt-Műnster group trial NHL-BFM 90. Blood 1999; 94: 3294-3360
11. Patte K, Auperin A, Michon J, et al. The Société Francaise d’Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001; 97: 3370-3379.
12. Atra A, Imeson JD, Hobson R, et al. Improved outcome in children with advanced stage B-cell non-Hodgkin’s lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol. Br J Cancer 2000; 82: 1396-1402.
13. Patte K, Auperin A, Gerrard M. et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 2007; 109: 2773-2780.
14. Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration Schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 2005; 105: 948-958.
15. Rosolen A, Pillon M, Garaventa A, et al. Anaplastic large cell lymphoma treated with a leukemia-like therapy. Cancer 2005; 104: 2133-2140.
16. Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Műnster Group trial NHL-BFM 90. Blood 2001; 97: 3699-3706.
17. Williams DM, Hobson R, Imeson J, et al. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on the United Kingdom Children’s Cancer Study Group chemotherapy regimens. Br J Haematol 2002; 117: 812-820.
18. Lowe EJ, Sposto R, Perkins SL, et al. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: Final results of Children’s Cancer Group Study 5941. Pediatr Blood Cancer 2009; 52: 335-339.
19. Bubanská E, Stančoková T, Škripková Š. Príčiny neúspechov pri liečbe NHL v súbore detského onkocentra Banská Bystrica. Čes-slov Pediat 2002; 57: 647
20. Bubanská E, Stančoková T, Škripková Š, Oravcová Z, Dluholucký S. Results of the treatment of malignant lymphomas in childhood – a review of 16 years period. Med Pediat Oncol 1997; 29: 470.
21. Bubanská E, Kaiserová E, Oravkinová I, Petržalková D, Horáková J. in: Zborník abstraktov: XVI. konferencia detských hematológov a onkológov SR a ČR, 3.-5. nov. 2006, Podbanské. Banská Bystrica, PRO, 2006; 92.
22. Damm-Welk C, Busch K, Burkhardt B, et al. Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by quantitative PCR in pediatric NPM-ALK positive anaplastic large-cell lymphoma. Blood 2007; 110: 670-677.
23. Le Deley MC, Reiter A, Williams D, et al. Prognostic factors in childhood anaplastic large cell lymphoma: Results of a large European intergroup study. Blood 2008; 111: 1560-1566.
24. Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved cell lymphoma: a pediatric oncology group study. J Clin Oncol 1996; 14: 1252-1261.
25. Attarbaschi A, Dworzak M, Steiner M, et al. Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: A population-based analysis of the Austrian cooperative study group. Pediatr Blood Cancer 2005; 44: 70-76.
26. Brugieres L, Quartier P, Le Deley MC, et al. Relapses of childhood anaplastic large-cell lymphoma: Treatment results in a series of 41 children- a report from French Sosiety of Pediatric Oncology. Ann Oncol 2000; 11: 53-58.
27. Stockklausner C, Behnisch W, Mechterscheimer G, et al. Long-term remission of children with relapsed and secondary anaplastic large cell non-hodgkin lymphoma (ALCL) following treatment with pulsed dexamethasone and low dose etoposide. Pediatr Blood Cancer 2008; 50: 126-129.
28. Fujita N, Mori T, Mitsui T, et al. The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhhood B-cell Non-Hodgkin Lymphoma and mature B-cell leukemia: A retrospective analysis of enrolled cases in Japan. Pediatr Blood Cancer 2008; 51: 188-192.
29. Feugier P, Van Hoff A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe dęEtude des Lymphomes de lęAdulte. J Clin Oncol 2005; 23: 4117-4126.
30. Pfreundschuh M, Trűmper L, Ősterborg A, et al. CHOP-like chemotherapy plus rituximab prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
31. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684-3688.
32. Griffin TC, Weitzman S, Weinstein H, et al. A study of Rituximab and Ifosfamide, Carboplatin and Etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: A report from the Children’s Oncology Group. Pediatr Blood Cancer 2009; 52: 177-181.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2010 Issue 1
Most read in this issue
- Unsuspected 18F-FDG PET/CT positive findings in the response evaluation or follow-up of non-Hodgkin’s lymphoma patients
- The changes in the nomenclature, classification and diagnostic criteria of myeloproliferative disorders according WHO classification 2008
- News in classification of MDS and evaluation of prognosis by WPSS
- Non-Hodgkinęs lymphomas in childhood in Slovak republic – the incidence and treatment results